Xanthohumol and Viral Infections (XL)

Xanthohumol in the Prevention of Virus-mediated Upper Respiratory Tract Infections in Humans

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06286657

Enrollment

100

Registered

2024-02-29

Start date

2023-08-01

Completion date

2025-12-30

Last updated

2025-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection Viral

Brief summary

The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections.

Detailed description

In this placebo-controlled study, blood is taken on the first day of the study, followed by a 90-day intervention with xanthohumol or a placebo, which is taken twice daily. Blood samples will be taken on day 0, day 45 and day 90. Should the study participants develop a respiratory infection during the study, they will be asked to perform a self-test.

Interventions

DIETARY_SUPPLEMENTXanthohumol

Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days

DIETARY_SUPPLEMENTPlacebo

Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy * BMI \>18 kg/m² or \< 28kg/m²

Exclusion criteria

* food intolerances * food allergies * chronic inflammatory diseases * metabolic diseases * viral or bacterial infections within the last 3 weeks of inclusion * intake of immunosuppressive medication * severe acute respiratory syndrome coronavirus type 2-infection in the last 4 months * influenza infection in the current flu season

Design outcomes

Primary

Measure	Time frame	Description
Changes in severity and duration of viral infections	90 days	Changes in score of Wisconsin Upper Respiratory Symptom Survey

Secondary

Measure	Time frame	Description
Changes in blood lipid levels	90 days	Changes in triglyceride levels (mg/dl) and cholesterol levels (mg/dl)
Changes in cognitive skills	90 days	Assessment of cognitive processes using stroop test

Countries

Austria

Contacts

Primary ContactIna Bergheim, Prof. Dr.

ina.bergheim@univie.ac.at+43-1-4277-54981

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026